New targeted therapy aims to extend life in stomach cancer

NCT ID NCT06649292

Recruiting now Disease control Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests a new drug, SHR-A1904, in 524 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). Participants receive either SHR-A1904 or standard chemotherapy. The main goal is to see if the new drug helps people live longer. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1904 (an antibody-drug conjugate targeting CLDN18.2)
What this could lead to: If successful, this could provide a new targeted treatment option for people with advanced gastric cancer whose tumors have a specific marker (CLDN18.2).
What could go wrong: This is a Phase 3 trial, but the drug is still experimental. It may not improve survival compared to current chemotherapies, and side effects from the targeted therapy could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECOND-LINE ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.